Hagerman Allison 4

What Happened

• Allison Hagerman, Vice President of Product Development at Oncolytics Biotech Inc. (ONCY), made an open‑market purchase of 10,000 shares on February 12, 2026 at $0.83 per share, for a total of $8,298. This was a direct purchase (transaction code P), not an option exercise or award.

Key Details

• Transaction date and price: 2026-02-12 @ $0.83 per share.
• Total value: $8,298.
• Filing date / accession: Form 4 filed 2026-02-13 (Accession No. 0001493152-26-006543).
• Shares owned after transaction: Not specified in the provided filing details.
• Notable footnotes: None reported (no 10b5‑1 plan, tax withholding, gift, or exercise indicated).
• Timeliness: Filing appears timely (transaction 2026-02-12, Form 4 filed 2026-02-13).

Context

• This was a straightforward open‑market purchase (code P). Purchases by company insiders can be more informative than sales because they may signal personal buying interest, but this single, relatively small transaction ($8.3k) should be viewed as only one data point and not proof of future stock performance.